Lopes SR, Martins C, Teixeira M, Tomás D. Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis. World J Gastroenterol 2024; 30(34): 3929-3931 [DOI: 10.3748/wjg.v30.i34.3929]
Corresponding Author of This Article
Claudio Martins, MD, Doctor, Department of Gastroenterology, Unidade Local de Saúde da Arrábida-Hospital de São Bernardo, Rua Camilo Castelo Branco, Setúbal 2910-446, Portugal. cmartins1@campus.ul.pt
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Sep 14, 2024; 30(34): 3929-3931 Published online Sep 14, 2024. doi: 10.3748/wjg.v30.i34.3929
Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis
Sara R Lopes, Claudio Martins, Madalena Teixeira, David Tomás
Sara R Lopes, Claudio Martins, Madalena Teixeira, David Tomás, Department of Gastroenterology, Unidade Local de Saúde da Arrábida-Hospital de São Bernardo, Setúbal 2910-446, Portugal
Author contributions: Lopes SR and Martins C analyzed the data and wrote the manuscript; All authors have read and approved the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Claudio Martins, MD, Doctor, Department of Gastroenterology, Unidade Local de Saúde da Arrábida-Hospital de São Bernardo, Rua Camilo Castelo Branco, Setúbal 2910-446, Portugal. cmartins1@campus.ul.pt
Received: April 14, 2024 Revised: August 10, 2024 Accepted: August 23, 2024 Published online: September 14, 2024 Processing time: 148 Days and 21.1 Hours
Abstract
Tofacitinib is an oral small-molecule Janus kinase (JAK) inhibitor that preferentially inhibits JAK1 and JAK3. Its efficacy in inducing and maintaining remission in ulcerative colitis (UC) as well as its safety profile has been demonstrated in multicenter, randomized, double-blind, placebo-controlled trials. Additionally, real-world studies evaluating the effectiveness and adverse effects of tofacitinib have been conducted, affirming its clinical efficacy in moderate-to-severe UC.
Core Tip: Tofacitinib, an oral small-molecule agent, has proven efficacy in inducing and maintaining remission among patients with moderate-to-severe ulcerative colitis. Real-world studies have showcased its effectiveness and safety profile to treat ulcerative colitis, primarily within Western countries. There have been a limited number of studies conducted on Asian patients.
